DE60224299D1 - Kombinationsmedikationen mit einem selektiven cyclooxygenase-2-inhibitor - Google Patents

Kombinationsmedikationen mit einem selektiven cyclooxygenase-2-inhibitor

Info

Publication number
DE60224299D1
DE60224299D1 DE60224299T DE60224299T DE60224299D1 DE 60224299 D1 DE60224299 D1 DE 60224299D1 DE 60224299 T DE60224299 T DE 60224299T DE 60224299 T DE60224299 T DE 60224299T DE 60224299 D1 DE60224299 D1 DE 60224299D1
Authority
DE
Germany
Prior art keywords
inhibitor
growth factor
selective cyclooxygenase
factor receptor
receptor tyrosine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60224299T
Other languages
English (en)
Other versions
DE60224299T2 (de
Inventor
Ying-Nan Pan Chen
Peter Lassota
Alexander Wallace Wood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Application granted granted Critical
Publication of DE60224299D1 publication Critical patent/DE60224299D1/de
Publication of DE60224299T2 publication Critical patent/DE60224299T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE60224299T 2001-10-25 2002-10-24 Kombinationsmedikationen mit einem selektiven cyclooxygenase-2-inhibitor Expired - Lifetime DE60224299T2 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US34473401P 2001-10-25 2001-10-25
US34473501P 2001-10-25 2001-10-25
US344734P 2001-10-25
US344735P 2001-10-25
US33603301P 2001-11-15 2001-11-15
US336033P 2001-11-15
PCT/EP2002/011924 WO2003035047A2 (en) 2001-10-25 2002-10-24 Combinations comprising a selective cyclooxygenase-2 inhibitor

Publications (2)

Publication Number Publication Date
DE60224299D1 true DE60224299D1 (de) 2008-02-07
DE60224299T2 DE60224299T2 (de) 2008-12-11

Family

ID=27407094

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60224299T Expired - Lifetime DE60224299T2 (de) 2001-10-25 2002-10-24 Kombinationsmedikationen mit einem selektiven cyclooxygenase-2-inhibitor

Country Status (23)

Country Link
US (2) US20050043409A1 (de)
EP (1) EP1441714B1 (de)
JP (1) JP2005506366A (de)
KR (1) KR100954625B1 (de)
CN (1) CN100506224C (de)
AT (1) ATE381930T1 (de)
AU (2) AU2006252156A1 (de)
BR (1) BR0213486A (de)
CA (1) CA2464309C (de)
CY (1) CY1108045T1 (de)
DE (1) DE60224299T2 (de)
DK (1) DK1441714T3 (de)
ES (1) ES2295428T3 (de)
HK (1) HK1068261A1 (de)
HU (1) HUP0600235A3 (de)
IL (1) IL161462A0 (de)
MX (1) MXPA04003878A (de)
NZ (2) NZ532418A (de)
PL (1) PL369305A1 (de)
PT (1) PT1441714E (de)
RU (1) RU2333754C2 (de)
SI (1) SI1441714T1 (de)
WO (1) WO2003035047A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0223341D0 (en) * 2002-10-08 2002-11-13 Groningen Acad Ziekenhuis Organic compounds
ES2314444T3 (es) 2003-08-29 2009-03-16 Pfizer Inc. Tienopiridina-fenilacetaminasy sus derivados utiles como nuevos agentes antiangiogenicos.
AU2004273615B2 (en) * 2003-09-23 2009-01-15 Novartis Ag Combination of a VEGF receptor inhibitor with a chemotherapeutic agent
WO2005027973A2 (en) * 2003-09-23 2005-03-31 Novartis Ag Combinations of a vegf receptor inhibitor with other therapeutic agents
KR100807920B1 (ko) 2003-12-23 2008-02-27 화이자 인코포레이티드 신규한 퀴놀린 유도체
JO2596B1 (en) * 2004-11-30 2011-02-27 نوفارتيس ايه جي Compositions include epothelones and tyrosine protein kinase inhibitors and their pharmaceutical uses
NZ570381A (en) * 2006-02-09 2011-02-25 Daiichi Sankyo Co Ltd Anti-cancer pharmaceutical composition
EP2065054A1 (de) 2007-11-29 2009-06-03 Bayer Schering Pharma Aktiengesellschaft Kombinationen mit einem Prostaglandin und Verwendungen davon
AR077975A1 (es) 2009-08-28 2011-10-05 Irm Llc Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina
EP2776037B1 (de) 2011-11-11 2019-01-09 Novartis AG Methode zur behandlung einer proliferativen erkrankung
MD565Z (ro) * 2012-05-23 2013-07-31 Институт Генетики, Физиологии И Защиты Растений Академии Наук Молдовы Procedeu de tratare a seminţelor de sfeclă de zahăr

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA67732C2 (uk) * 1996-10-15 2004-07-15 Г.Д. Сьорл & Ко. Інгібітори циклооксигенази-2 для лікування і попередження неоплазії та спосіб лікування
US6380394B1 (en) * 1996-12-13 2002-04-30 The Scripps Research Institute Epothilone analogs
CO4950519A1 (es) * 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
US6034256A (en) * 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
CO4960662A1 (es) * 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
US6025353A (en) * 1997-11-19 2000-02-15 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors as anti-angiogenic agents
US6887893B1 (en) * 1997-12-24 2005-05-03 Sankyo Company, Limited Methods and compositions for treatment and prevention of tumors, tumor-related disorders and cachexia
PL349216A1 (en) * 1998-12-23 2002-07-01 Searle & Co Method of using a cyclooxygenase-2 inhibitor and a matrix metalloproteinase inhibitor as a combination therapy in the treatment of neoplasia
WO2001012227A1 (en) * 1999-08-12 2001-02-22 American Cyanamid Company Nsaid and efgr kinase inhibitor containing composition for the treatment or inhibition of colonic polyps and colorectal cancer
YU35102A (sh) * 1999-12-03 2005-03-15 Pfizer Products Inc. Derivati heterociklo-alkilsulfonil pirazola kao anti- inflamatorni/analgetički agensi
ITMI992711A1 (it) * 1999-12-27 2001-06-27 Novartis Ag Composti organici
CA2400197A1 (en) * 2000-02-17 2001-08-23 Merck & Co., Inc. Treatment or prevention of prostate cancer with a cox-2 selective inhibiting drug
JP2003523390A (ja) * 2000-02-25 2003-08-05 メルク エンド カムパニー インコーポレーテッド チロシンキナーゼ阻害薬
AU3217501A (en) * 2000-03-03 2001-09-12 Pfizer Prod Inc Pyrazole ether derivatives as anti-inflammatory/analgesic agents
TWI310684B (en) * 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer

Also Published As

Publication number Publication date
WO2003035047A2 (en) 2003-05-01
EP1441714A2 (de) 2004-08-04
NZ552335A (en) 2008-11-28
IL161462A0 (en) 2004-09-27
PL369305A1 (en) 2005-04-18
KR100954625B1 (ko) 2010-04-27
DK1441714T3 (da) 2008-03-31
WO2003035047A3 (en) 2003-10-23
HK1068261A1 (en) 2005-04-29
AU2006252156A1 (en) 2007-01-18
CY1108045T1 (el) 2013-09-04
CN100506224C (zh) 2009-07-01
JP2005506366A (ja) 2005-03-03
US20110046190A1 (en) 2011-02-24
SI1441714T1 (sl) 2008-06-30
MXPA04003878A (es) 2004-07-08
KR20040048992A (ko) 2004-06-10
CA2464309C (en) 2012-01-03
CN1575168A (zh) 2005-02-02
HUP0600235A2 (en) 2007-02-28
DE60224299T2 (de) 2008-12-11
ES2295428T3 (es) 2008-04-16
NZ532418A (en) 2007-02-23
US20050043409A1 (en) 2005-02-24
RU2333754C2 (ru) 2008-09-20
EP1441714B1 (de) 2007-12-26
AU2010200433A1 (en) 2010-02-25
BR0213486A (pt) 2005-05-10
CA2464309A1 (en) 2003-05-01
ATE381930T1 (de) 2008-01-15
HUP0600235A3 (en) 2008-04-28
RU2004116069A (ru) 2005-06-10
PT1441714E (pt) 2008-03-10

Similar Documents

Publication Publication Date Title
HK1068261A1 (en) Combinations comprisinga selective cyclooxygenase-2 inhibitor
NO20044475L (no) 2-(2,6-diklorfenyl)-diarulimidazoler
IL154949A0 (en) Imidazole derivatives as raf kinase inhibitors
NO20034204D0 (no) Farmasöytiske kombinasjoner til behandling av kreft
DK1423384T3 (da) Pyridinderivater som Raf kinaseinhibitorer
PT1268472E (pt) Inibidores 3-aminopirazolicos de cinases dependentes da ciclina
HK1080733A1 (en) Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonates, a cox-2 inhibitor and a taxol
DE60228616D1 (de) Verwendung von anastrozol zur behandlung von postmenopausalen frauen mit frühzeitigem brustkrebs
DE60214019D1 (de) Stickstoff enthaltende heterozyklen und ihre verwendung als raf inhibitoren
AU3919001A (en) Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid (2-mtdc) and/or physiologically compatible salts for treating and/or preventing cancers
BRPI0415355A (pt) triarilimidazóis
ATE386029T1 (de) Urokinase-inhibitoren
WO2002074735A3 (de) Biurethanderivate
ATE267194T1 (de) Medikamente geeignet zur behandlung von proliferativen erkrankungen
ATE329597T1 (de) Die verwendung von einer 4- pyridylmethylphtalazine enthaltenden kombination zur behandlung von tumoren
ATE400268T1 (de) Bisindolylmaleimid zur behandlung von prostatakrebs und akt-vermittelten erkrankungen
ATE423780T1 (de) Makrozyclen zur behandlung von krebserkrankungen
ATE373661T1 (de) 1.3.4-triaza-phenalen- und 1,3,4,6- tetraazaphenalen-derivative
UA49216A (uk) Засіб для лікування ускладнень після видалення злоякісних новоутворень шкіри
UY27768A1 (es) 2-(2,6- diclorofenil)-diarilimidazoles
ATE297745T1 (de) Chemische modifizierung von harn von säugern
WO2004044226A3 (en) Induction of cellular senescence by cdk4 disruption for tumor supression and regression

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336

8328 Change in the person/name/address of the agent

Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN